{'52WeekChange': -0.6435319,
 'SandP52WeekChange': None,
 'address1': '25-28 North Wall Quay',
 'address2': 'IFSC',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 0.8188,
 'askSize': 1000,
 'averageDailyVolume10Day': 22846500,
 'averageVolume': 9688971,
 'averageVolume10days': 22846500,
 'beta': 2.497854,
 'beta3Year': None,
 'bid': 0.8111,
 'bidSize': 900,
 'bookValue': 0.209,
 'category': None,
 'circulatingSupply': None,
 'city': 'Dublin',
 'companyOfficers': [],
 'country': 'Ireland',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 0.8399,
 'dayLow': 0.794,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -0.81,
 'enterpriseToRevenue': 7.569,
 'enterpriseValue': 64842396,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 0.7731714,
 'fiftyTwoWeekHigh': 2.77,
 'fiftyTwoWeekLow': 0.485,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 99396917,
 'forwardEps': -0.42,
 'forwardPE': -1.9757143,
 'fromCurrency': None,
 'fullTimeEmployees': 162,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.01232,
 'heldPercentInstitutions': 0.43408,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/nabriva.com',
 'longBusinessSummary': 'Nabriva Therapeutics plc, a biopharmaceutical '
                        'company, engages in the development and '
                        'commercialization of novel anti-infective agents to '
                        "treat serious infections. The company's lead product "
                        'candidate is lefamulin, a semi-synthetic '
                        'pleuromutilin antibiotic for the treatment of '
                        'community-acquired bacterial pneumonia; for the '
                        'treatment of acute bacterial skin and skin structure '
                        'infection; and that is in Phase I clinical trial for '
                        'the treatment of pediatric infections, as well as '
                        'sexually transmitted infections, osteomyelitis, and '
                        'prosthetic joint infections. It is also developing '
                        'CONTEPO, an epoxide antibiotic for use in treating '
                        'complicated urinary tract infections, as well as is '
                        'in Phase I clinical trial for peri-operative '
                        'prophylaxis. The company was formerly known as '
                        'Nabriva Therapeutics Forschungs GmbH and changed its '
                        'name to Nabriva Therapeutics plc in 2007. Nabriva '
                        'Therapeutics plc was incorporated in 2005 and is '
                        'headquartered in Dublin, Ireland.',
 'longName': 'Nabriva Therapeutics plc',
 'market': 'us_market',
 'marketCap': 118632352,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_25727861',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -85806000,
 'nextFiscalYearEnd': 1640908800,
 'open': 0.8103,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.01,
 'phone': '353 1 649 2000',
 'previousClose': 0.8377,
 'priceHint': 4,
 'priceToBook': 3.9703348,
 'priceToSalesTrailing12Months': 13.847595,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 0.8399,
 'regularMarketDayLow': 0.794,
 'regularMarketOpen': 0.8103,
 'regularMarketPreviousClose': 0.8377,
 'regularMarketPrice': 0.8103,
 'regularMarketVolume': 3121058,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 142964992,
 'sharesPercentSharesOut': 0.044099998,
 'sharesShort': 6299241,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 4058925,
 'shortName': 'Nabriva Therapeutics plc',
 'shortPercentOfFloat': 0.044299997,
 'shortRatio': 0.46,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'NBRV',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.064,
 'twoHundredDayAverage': 0.9118561,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '8404939f-f472-37c5-b085-ec6599bb9f74',
 'volume': 3121058,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.nabriva.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '1'}